Compare Gilead Sciences, Inc. (GILD) vs Zillow Group Inc Class C (Z) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Zillow Group Inc Class C — how do they compare? Gilead Sciences, Inc. trades at $148.72 (market cap $182.40B), while Zillow Group Inc Class C trades at $28.64 (market cap $6.59B). The key difference: Gilead Sciences, Inc. is far larger — about 27.7× Zillow Group Inc Class C's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Zillow Group Inc Class C pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Zillow Group Inc Class C for 39 Days on average.
| GILD | Z | |
|---|---|---|
Market Cap | $182.40B | $6.59B |
Volume | 4,469,821 | 9,134,294 |
Sector | Health | Media |
52-Week High | $155.80 | $78.04 |
52-Week Low | $116.74 | $27.13 |
Typical Hold Time | 111 Days | 39 Days |
Enterprise Value | $205.46B | $6.47B |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
Zillow Group (Z) trades at $28.65, up 5.02% over 24 hours, with a bullish technical signal despite mixed moving averages. The company reported revenue of $2.58 billion in 2025, turning a net profit of $23 million after a loss in 2024, and shows improving margins. Recent news highlights AI integration in real estate and resolution of an FTC lawsuit, while the housing market faces affordability challenges.
The outlook is cautiously optimistic with a consensus price target of $60.33, implying significant upside, but risks include sensitivity to mortgage rates and competitive pressures. Earnings have beaten expectations in two of the last three quarters, supporting growth potential amid a volatile housing sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Zillow Group Inc Class C
Zillow Group is an online real estate company that simplifies buying, selling, renting, and financing properties. It partners with agents, brokers, and landlords, combining technology with quality service. Its brands include Zillow, Trulia, StreetEasy, and Hotpads.
Read more on Z →
